trending Market Intelligence /marketintelligence/en/news-insights/trending/L_pYM4bg_eVYyKrR9oA6qQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

LogicBio, Takeda collaborating to develop therapy for rare disease in children

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

LogicBio, Takeda collaborating to develop therapy for rare disease in children

LogicBio Therapeutics Inc. has entered a research collaboration with Tokyo-based Takeda Pharmaceutical Co. Ltd. to further develop an experimental treatment for a rare genetic disease in children.

Cambridge, Mass.-based LogicBio's LB-301 uses the proprietary genome editing technology GeneRide to treat Crigler-Najjar syndrome, a rare pediatric disease caused by a deficiency in the liver‐specific UGT1A1 gene. The condition leads to severely high levels of unconjugated bilirubin, a substance found in bile, in the blood starting at birth.

The disease carries a lifelong risk of permanent neurological damage and death. Currently, treatment for the disease includes daily, intense phototherapy for about 12 hours, but this therapy becomes less effective with age, and liver transplantation becomes the only therapeutic option for survival.

LogicBio, which develops medicines to treat rare diseases in pediatric patients with significant unmet medical needs, and Takeda will work together to further research and develop LB-301. Takeda will provide funding for the research program.

Takeda will also have an option to negotiate an exclusive, worldwide license to LogicBio's LB-301 program.

Financial terms of the agreement were not disclosed.